The estimated Net Worth of Sushma Shivaswamy is at least $1.56 Milión dollars as of 10 September 2020. Sushma Shivaswamy owns over 40,000 units of XBiotech Inc stock worth over $133,722 and over the last 7 years he sold XBIT stock worth over $0. In addition, he makes $1,426,130 as Chief Scientific Officer at XBiotech Inc.
Sushma has made over 2 trades of the XBiotech Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 40,000 units of XBIT stock worth $300,000 on 10 September 2020.
The largest trade he's ever made was exercising 40,000 units of XBiotech Inc stock on 10 September 2020 worth over $300,000. On average, Sushma trades about 5,563 units every 73 days since 2017. As of 10 September 2020 he still owns at least 20,668 units of XBiotech Inc stock.
You can see the complete history of Sushma Shivaswamy stock trades at the bottom of the page.
Dr. Sushma Shivaswamy Ph.D. serves as Chief Scientific Officer of the Company. As CSO Dr. Shivaswamy oversees all scientific and technical operations with respect to research and development and Good Manufacturing Practice production of antibody. Dr. Shivaswamy previously served as the Company’s Vice President of Research and Development since January 2015 where she led teams involved in various Research & Development projects at XBiotech including Antibody Discovery, Cell Line Development, and pre-clinical toxicology and efficacy studies using animal models. Dr. Shivaswamy has been with the Company since 2009 also holding positions of Director of Research & Development (2011-2015) and Senior Scientist (2009-2011). Prior to joining XBiotech, Dr. Shivaswamy was a postdoctoral researcher at the Center for Systems and Synthetic Biology at the University of Texas at Austin. She has a Ph.D. degree in Molecular Biology from the Center for Cellular and Molecular Biology, India. Dr. Shivaswamy’s academic studies have involved elucidating mechanisms for regulation of gene expression.
As the Chief Scientific Officer of XBiotech Inc, the total compensation of Sushma Shivaswamy at XBiotech Inc is $1,426,130. There are 2 executives at XBiotech Inc getting paid more, with John Simard having the highest compensation of $10,810,400.
Sushma Shivaswamy is 41, he's been the Chief Scientific Officer of XBiotech Inc since 2017. There are 9 older and no younger executives at XBiotech Inc. The oldest executive at XBiotech Inc is Peter Libby, 73, who is the Independent Director.
Sushma's mailing address filed with the SEC is 3443 SHIRAZ LOOP, , ROUND ROCK, TX, 78665.
Over the last 9 years, insiders at XBiotech Inc have traded over $50,443,920 worth of XBiotech Inc stock and bought 1,428,502 units worth $11,921,113 . The most active insiders traders include Street Financial S.A. Bay, Fondation Rennes a W Thorpe Mckenzie. On average, XBiotech Inc executives and independent directors trade stock every 48 days with the average trade being worth of $1,053,782. The most recent stock trade was executed by W Thorpe Mckenzie on 16 December 2021, trading 250,000 units of XBIT stock currently worth $2,500,000.
xbiotech is developing a first-in-class monoclonal antibody (mabp1) to inhibit chronic inflammation. chronic (sterile) inflammatory responses are involved in the progression of many serious and common diseases. mabp1 is being investigated in many important areas of medicine, including: cancer, leukemia (phase 1); type 2 diabetes (phase2); psoriasis (phase 2); and vascular disease (phase 2). mabp1 is a true human™ antibody cloned from a natural human immune response and—unlike currently marketed antibodies—it has not undergone any modification to alter its function. it has exhibited the best potential tolerability and safety during the clinical trials. xbiotech has established a current good manufacturing practices (cgmp) program to commercialize its lead product candidate. the company has purchased land and designed a commercial-scale plant with 25,000l total bioreactor capacity. construction of the facility is planned to commence in 4th quarter 2011..
XBiotech Inc executives and other stock owners filed with the SEC include: